MedTrace Logo

Safety Study of Levocetirizine and Fexofenadine

NCT01586091 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-10-04

Study results available
· View outcomes & findings →

Summary

This Study is to comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal, flare and itch Response.

Conditions

  • Pruritus
  • Chronic Urticaria
  • Allergic Rhinitis

Interventions

DRUG

Levocetirizine Oral Tablet

DRUG

Fexofenadine 60 Mg Oral Tablet

DRUG

Placebo Oral Tablet

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Marcus Maurer, MD · Charite Universitätsmedizin Berlin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-11-30
Completion
2012-02-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01586091 on ClinicalTrials.gov